Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 13, Issue 4, 2010, Pages 589-606

  Liu, Yinghui ^a   Sun, Changshan ^a   Hao, Yanru ^a,b   Jiang, Tongying ^a   Zheng, Li ^a   Wang, Siling ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Shenyang B Braun Pharmaceutical Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DODECYL SULFATE SODIUM; HYDROXYPROPYLMETHYLCELLULOSE; NANOPARTICLE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTACT ANGLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRY POWDER; FEMALE; HYDROGEN BOND; HYDROPHOBICITY; INFRARED SPECTROSCOPY; MALE; MAXIMUM PLASMA CONCENTRATION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRECIPITATION; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY PHOTOELECTRON SPECTROSCOPY; X RAY POWDER DIFFRACTION;

EID: 78650366422     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3530j     Document Type: Article

References (36)

1. Radtke M. Pure drug nanaoparticles for the formulation of pooly soluble drugs. New Drugs, 2001; 3: 62-68.
2. Lipinski C. Poor aqueous solubility-an industry wide problem in drug discovery. Am Pharm Rev, 2002; 5: 82-85.
3. Dressmann JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci, 2000; 11: 73-80.
4. Kesisoglou F, Panmai S, Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev, 2007; 5916: 31-44.
5. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol, 2004; 56: 827-840.
6. Rabinow BE. Nanosuspensions in drug delivery. Nature rev Drug Disc, 2004; 3: 785-796.
7. Wong S M, Kellaway IW, Murdan S. Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles. Int J Pharm, 2006; 317: 61-68.
8. Muller RH, Jacobs C, Kayser O. Nanosuspension as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 2001; 47: 3-19.
9. Guo Z, Zhang M, Li H, Wang E, Kougouslos E. Effect of ultrasound on antisolvent crystallization process. J Cryst Growth, 2005; 273: 555-563.
10. Louhi-Kultanen M, Karjalainen M, Rananen J, Huhtanen M, Kallas J. Crystallization of glycine with ultrasound. Int J Pharm, 2006; 320: 23-29.
11. Dhumal Ravindra S, Biradar Shailesh V, Yamamura Shigeo, Paradkar Anant R, York Peter. Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability. Eur J Pharm Biopharm; 2008; 70: 109-115.
12. Verma Sudhir, Gokhaleb Rajeev, Burgessa Diane J. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm, 2009; 380: 216-222.
13. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 1995; 12: 413-420.
14. Detrembleur C, De Nayer J, Den Hecke A Van. Celecoxib improves the efficiency of the locomotor mechanism in patients with knee osteoarthritis. A randomised, placebo, double-blind and cross-over trial. Osteoarthr Cartilage, 2005; 13: 206-210.
15. Kivitz AJ, Espinoza LR, Sherrer YR, Liu-Dumaw M, West CR. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis. Semin Arthritis Rheum, 2007; 37: 164-173.
16. Yelland MJ, Nikles CJ, Mcnairn N, Del Mar CB, Schluter PJ, Brown RM. Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials. Rheumatology (Oxford), 2007; 46: 135-140.
17. Reddy MN, Rehana Tasneem, Ramakrishna S, Chowdary KPR, Diwan PV. β-cyclodextrin complexes of celecoxib: molecular-modeling characterization, and dissolution studies. AAPS PharmSci, 2004; 6 (1): 1-9.
18. Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, Yan B, Maziasz TJ, Cook CS, Karim A. Pharmacokinetics of celecoxib after oral administration in dogs and humans: Effect of food and site of absorption. J Pharmacol Exp Ther, 2001; 297: 638-645.
19. Shono Y, Jantratid E, Janssen N, Kesisoglou F, Mao Y, Vertzoni M, Reppas C, Dressman JB. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur J Pharm Biopharm, 2009; 73: 107-114.
20. Rawat S, Jain SK. Solubility enhancement of celecoxib using β-cyclodextrin inclusion complexes. Eur J Pharm Biopharm, 2004; 57: 263-267.
21. Subramanian N, Ray S, Ghosal SK, Bhadra R, Moulik SP. Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib. Biol Pharm Bull, 2004; 27: 1993-1999.
22. Garti N, Avrahami M, Aserin A. Improved solubilization of celecoxib in utype nonionic microemulsions and their structural transitions with progressive aqueous dilution. J Colloid Interface Sci, 2006; 299: 352-365.
23. Homar M, Ubrich N, El Ghazouani F, Kristl J, Kerc J, Maincent P. Influence of polymers on the bioavailability of microencapsulated celecoxib. J Microencapsul, 2007; 24: 621-633.
24. Andrej Dolenc, Julijana Kristl, Saša Baumgartner, Odon Planinšek. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int J Pharm, 2009; 376: 204-212.
25. Patlolla Ram R, Chougule Mahavir, Patel Apurva R, Jackson Tanise, Tata Prasad NV, Singh Mandip. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release, 2010; 144: 233-241.
26. Margulis-Goshen Katrin, Kesselman Ellina, Danino Dganit, Magdassi Shlomo. Formation of celecoxib nanoparticles from volatile microemulsions. Int J Pharm, 2010; 393: 230-237.
27. Bunjes Heike, Unruh Tobias. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv Drug Deliv Rev, 2007; 59: 379-402.
28. Chawla G, Gupta P, Thilagavathi R, Chakraborti A, Bansal AK. Characterization of solid-state forms of celecoxib. Eur J Pharm Sci, 2003; 20: 305-317.
29. Raghavan SL, Schuessel K, Davis A, Hadgraft J. Formation and stabilisation of triclosan colloidal suspensions using supersaturated systems. Int J Pharm, 2003; 261: 153-158.
30. Li XS, Wang JX, Shen ZG, Zhang PY, Chen JF, Yun J. Preparation of uniform prednisolone microcrystals by a controlled microprecipitation method. Int J Pharm, 2007; 342, 26-32.
31. Smart BE. Fluorine substituent effect. J Fluorine Chem, 2001; 109: 3-11.
32. Dong Yuancai, Ng Wai Kiong, Shen Shoucang, Kim Sanggu, Tan Reginald BH. Preparation and characterization of spionolactone nanoparticles by antisolvent precipitation. Int J Pharm, 2009; 375: 84-88.
33. Gupta Venkadari Rammohan, Mutalik Srinivas, Patel Madhobhai M, Jani Girsh K. Spherical crystals of celecoxib to improve solubility, dissolution rate and miromeritic properties. Acta Pharm, 2007; 57: 173-184.
34. Paradkar AR, Pawar AP, Chordiya JK, Patil VB, Ketkar AR. Spherical crystallization of celecoxib. Drug Dev Ind Pharm, 2002; Vol. 28, No. 10: pp. 1213-1220.
35. Gupta P, Bansal AK. Devitrification of amorphous celecoxib. AAPS PharmSciTech, 2005; 6: E223-E230.
36. Kaushal AM, Bansal AK. Thermodynamic behavior of glassy state of structurally related compounds. Eur J Pharm BioPharm, 2008; 69: 1067-1076.